Sanofi’s Revamped Business Structure Includes Three New Pharma Units
This article was originally published in The Tan Sheet
Executive Summary
The French pharma said it will operate with five global business units beginning in January 2016: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.
You may also be interested in...
Sanofi CEO Sets Growth Target For Consumer Health Business
CEO Brandicourt looks to Alan Main to lead return to mid-single-digit growth for consumer brands.
Sanofi CEO Sets Growth Target For Consumer Health Business
CEO Brandicourt looks to Alan Main to lead return to mid-single-digit growth for consumer brands.
Sanofi Says Au Revoir To Viehbacher, But Is It Committing A Faux Pas?
The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.